FDA Tracker newsroom · PCAC

FDA schedules July PCAC vote on BPC-157, TB-500 and five more, what it means.

Jun 10, 2026 · Last reviewed Jul 24, 2026

The FDA's Pharmacy Compounding Advisory Committee will review seven peptides on July 23–24, 2026. The vote is advisory: a favorable recommendation leads to rulemaking, not instant availability. We'll publish the outcome the same day.

On July 23–24, 2026, the FDA's Pharmacy Compounding Advisory Committee (PCAC) will review a slate of peptides for the 503A bulk-compounding list. Day one covers BPC-157, KPV, TB-500, and MOTS-c; day two covers DSIP/Emideltide, Semax, and Epitalon.

PCAC is advisory. Its recommendation informs FDA rulemaking; it does not, by itself, make any peptide legal to compound or available to buy. A favorable vote would begin a rulemaking process, with realistic legitimate access no earlier than late 2026 into 2027.

We will publish the outcome the same day, in plain English, with the before-and-after status of every molecule reviewed, both the regulatory pill and the plain-English verdict dot.

Molecules in this update

• BPC-157 — FDA status
• TB-500 — FDA status
• KPV — FDA status
• MOTS-c — FDA status
• DSIP (Emideltide) — FDA status
• Semax — FDA status
• Epitalon — FDA status

Primary sources

• PCAC docket FDA-2025-N-6895 (regulations.gov)
• FDA Advisory Committee calendar

Reviewed by the Peptós.LIFE clinical team · Medical & regulatory review.

Compounded medications are not FDA-approved. PCAC is an advisory committee: a favorable vote leads to FDA rulemaking, not authorization and not next-day availability. Nothing here is medical advice, and no peptide is offered for sale on this page.

Get the alert when this status actually changes · Full FDA status board · All regulatory updates